T. Leal

Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study.

G. Sica, T. Owonikoko, S. Ramalingam, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development and characterization of patient-derived xenografts from non-small cell lung cancer brain metastases

I. Ong, A. Baschnagel, R. Kimple, 2020, Scientific Reports.

Impact of Radiation Dose to the Immune Cells in Unresectable or Stage III Non-Small Cell Lung Cancer in the Durvalumab Era.

J. Bradley, S. Ramalingam, K. Higgins, 2022, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

A Phase II Trial of Atezolizumab Plus Carboplatin Plus Pemetrexed Plus Bevacizumab in the Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer: Big Ten Cancer Research Consortium (BTCRC)- LUN 17-139.

N. Hanna, R. Gentzler, S. Althouse, 2022, Clinical lung cancer.

A Phase 1 – 2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC

Melissa L. Johnson, G. Curigliano, D. Morgensztern, 2021 .

Consolidation nivolumab plus ipilimumab or nivolumab alone following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: BTCRC LUN 16-081.

N. Hanna, S. Jalal, A. Ganti, 2022, Journal of Clinical Oncology.

A Phase I/II Study of Rovalpituzumab Tesirine in Combination With Nivolumab ± Ipilimumab in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer.

Melissa L. Johnson, G. Curigliano, D. Morgensztern, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non–small cell lung cancer previously treated with a PD‐1 or PD‐L1 inhibitor: Big Ten Cancer Research Consortium BTCRC‐LUN15‐029

N. Hanna, S. Perkins, A. Traynor, 2022, Cancer.

A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade.

T. Owonikoko, S. Ramalingam, Zhengjia Chen, 2022, Clinical lung cancer.

A phase 1/2 study of the highly selective EGFR inhibitor, BLU-701, in patients with EGFR-mutant non–small cell lung cancer (NSCLC).

D. Camidge, K. Goto, S. Gadgeel, 2022, Journal of Clinical Oncology.

A phase I study of R-(-)-gossypol (AT-101) in combination with cisplatin (P) and etoposide (E) in patients with advanced solid tumors and extensive-stage small cell lung cancer (ES-SCLC).

G. Wilding, J. Kolesar, J. Eickhoff, 2010, Journal of Clinical Oncology.

Ph1/2 study of Rova-T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC.

G. Curigliano, D. Morgensztern, B. Besse, 2019, Journal of Clinical Oncology.